Background: Association of proton pump inhibitor (PPI) exposure with acute myocardial infarction (AMI) risk in the Caucasian population remains under debate. Here, we clarified whether PPI exposure might be related to an increased new-onset AMI risk in an Asian population. Method: Data of 27,624 patients with PPI exposure followed by new-onset AMI development were extracted from Taiwan National Health Insurance Research Database and age- and sex-matched with 27,624 controls with PPIs exposure, but without subsequent AMI and ischemic heart disease development. The amount of PPI exposure was calculated based on the cumulative defined daily dose (cDDD) during the follow-up period. Subsequent AMI risk was measured after adjustments of demographic data and indication of PPI use. Results: AMI risk increased with an increase in PPI exposure: with cDDD ≤ 30 as the reference, the odds ratios (95% confidence intervals) for cDDDs of > 365 was 1.56 (1.45–1.69). All five PPI categories, including pantoprazole, lansoprazole, omeprazole, esomeprazole, and rabeprazole, increased AMI risk. Conclusions: Our study demonstrated long-term or high-dose PPI exposure associated with increased new-onset AMI risk in patients without a history of any ischemic heart disease. The underlying mechanisms of PPI-related cardiovascular effects deserve more investigation.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Aso, S., Imamura, H., et al. (2011). Incidence and mortality of acute myocardial infarction. A population-based study including patients with out-of-hospital cardiac arrest. International Heart Journal, 52(4), 197–202.
Yeh, R. W., Sidney, S., et al. (2010). Population trends in the incidence and outcomes of acute myocardial infarction. New England Journal of Medicine, 362(23), 2155–2165.
Reed, G. W., Rossi, J. E., et al. (2017). Acute myocardial infarction. Lancet, 389(10065), 197–210.
Rathore, V., Singh, N., et al. (2018). Risk factors for acute myocardial infarction: A review. Eurasian Journal of Medical Investigation, 2, 1–7.
Batchelor, R., Kumar, R., et al. (2018). Systematic review with meta-analysis: Risk of adverse cardiovascular events with proton pump inhibitors independent of clopidogrel. Alimentary Pharmacology & Therapeutics, 48(8), 780–796.
US Food and Drug Administration. (2013). Update of safety review-follow-up to the august 9, 2007, communication about the ongoing safety review of omeprazole and esomeprazole.
Lundell, L., Miettinen, P., et al. (2009). Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clinical Gastroenterology and Hepatology, 7(12), 1292–1298.
Manolis, A. A., Manolis, T. A., et al. (2020). Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? European Journal of Internal Medicine, 72, 15–26.
Shah, N. H., LePendu, P., et al. (2015). Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One, 10(6), e0124653.
Shih, C. J., Chen, Y. T., et al. (2014). Proton pump inhibitor use represents an independent risk factor for myocardial infarction. International Journal of Cardiology, 177(1), 292–297.
Sun, S., Cui, Z., et al. (2017). Proton pump inhibitor monotherapy and the risk of cardiovascular events in patients with gastro-esophageal reflux disease: A meta-analysis. Neurogastroenterology & Motility, 29(2), e12926.
Zhu, W., & Hong, K. (2017). Potential cardiovascular risks of proton pump inhibitors in the general population. International Heart Journal, 58(2), 163–166.
Turkiewicz, A., Vicente, R. P., et al. (2015). Revising the link between proton-pump inhibitors and risk of acute myocardial infarction-a case-crossover analysis. European Journal of Clinical Pharmacology, 71(1), 125–129.
Chen, M. H., Hsu, J. W., et al. (2018). Sexually transmitted infection among adolescents and young adults with attention-deficit/hyperactivity disorder: A nationwide longitudinal study. Journal of the American Academy of Child and Adolescent Psychiatry, 57(1), 48–53.
Chen, M. H., Lan, W. H., et al. (2016). Risk of developing type 2 diabetes in adolescents and young adults with autism spectrum disorder: A nationwide longitudinal study. Diabetes Care, 39(5), 788–793.
Chen, M. H., Pan, T. L., et al. (2015). Risk of stroke among patients with post-traumatic stress disorder: Nationwide longitudinal study. British Journal of Psychiatry, 206(4), 302–307.
Cheng, C. M., Chang, W. H., et al. (2017). Co-aggregation of major psychiatric disorders in individuals with first-degree relatives with schizophrenia: a nationwide population-based study. Molecular Psychiatry, 23(8), 1756–1763.
Cheng, C. L., Lee, C. H., et al. (2014). Validation of acute myocardial infarction cases in the national health insurance research database in taiwan. Journal of Epidemiology, 24(6), 500–507.
Charlson, M. E., Pompei, P., et al. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383.
Schillinger, W., Teucher, N., et al. (2007). Negative inotropy of the gastric proton pump inhibitor pantoprazole in myocardium from humans and rabbits: Evaluation of mechanisms. Circulation, 116(1), 57–66.
Yenisehirli, A., & Naseri, E. (2008). Omeprazole, lansoprazole and pantoprazole had no effect on blood pressure and electrocardiogram of anesthetized rat. Pharmacological Research, 58(1), 65–71.
Yenisehirli, A., & Onur, R. (2005). Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium. European Journal of Pharmacology, 519(3), 259–266.
Cooke, J. P. (2004). Asymmetrical dimethylarginine: The Uber marker? Circulation, 109(15), 1813–1818.
Cooke, J. P. (2010). DDAH: A target for vascular therapy? Vascular Medicine, 15(3), 235–238.
Ghebremariam, Y. T., LePendu, P., et al. (2013). Unexpected effect of proton pump inhibitors: Elevation of the cardiovascular risk factor asymmetric dimethylarginine. Circulation, 128(8), 845–853.
Lu, T. M., Chung, M. Y., et al. (2011). Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. International Journal of Cardiology, 153(2), 135–140.
Mittermayer, F., Krzyzanowska, K., et al. (2006). Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(11), 2536–2540.
Wilson, A. M., Shin, D. S., et al. (2010). Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vascular Medicine, 15(4), 267–274.
Clooney, A. G., Bernstein, C. N., et al. (2016). A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. Alimentary Pharmacology & Therapeutics, 43(9), 974–984.
Imhann, F., Bonder, M. J., et al. (2016). Proton pump inhibitors affect the gut microbiome. Gut, 65(5), 740–748.
Leonard, J., Marshall, J. K., et al. (2007). Systematic review of the risk of enteric infection in patients taking acid suppression. The American Journal of Gastroenterology, 102(9), 2047–2056.
Seldin, M. M., Meng, Y., et al. (2016). Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear Factor-kappaB. Journal of the American Heart Association. https://doi.org/10.1161/JAHA.115.002767.
Sun, X., Jiao, X., et al. (2016). Trimethylamine N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochemical and Biophysical Research Communications, 481(1–2), 63–70.
Tang, W. H., & Hazen, S. L. (2014). The contributory role of gut microbiota in cardiovascular disease. Journal of Clinical Investigation, 124(10), 4204–4211.
Zhu, W., Gregory, J. C., et al. (2016). Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell, 165(1), 111–124.
We thank Mr I-Fan Hu for his friendship and support.
The study was supported by a grant from Taipei Veterans General Hospital (V106B-020, V107B-010, V107C-181, V108B-012), Yen Tjing Ling Medical Foundation (CI-110-30), and Ministry of Science and Technology, Taiwan (107-2314-B-075-063-MY3, 108-2314-B-075-037). The funding source had no role in any process of our study. None of the aforementioned funding organizations had any role in the study design, data collection, analysis, interpretation of the result, writing of the report, and the ultimate decision to submit the paper for publication.
Conflict of Interest
All authors declared no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Handling Editor: Y. James Kang.
Below is the link to the electronic supplementary material.
About this article
Cite this article
Tseng, HJ., Cheng, CM., Tsai, SJ. et al. Proton Pump Inhibitor Exposure and Acute Myocardial Infarction Risk: A Nested Cohort Study. Cardiovasc Toxicol (2021). https://doi.org/10.1007/s12012-021-09637-2
- Proton pump inhibitor
- Acute myocardial infarction
- Cumulative defined daily dose